A total of 27 % of docetaxel patients had grade 3 or 4 neutropenia, and 29 % had alopecia of any grade; 14 % of erlotinib patients suffered grade 3 or 4 dermatological toxicities. (cancernetwork.com)
Mouse studies then confirmed that using the diuretic alongside the cancer drug erlotinib reversed resistance to the drug, and enabled it to kill lung cancer cells. (sciencedaily.com)
Mutated KRAS status was present in 22.7 % of docetaxel patients and 23.9 % of erlotinib patients. (cancernetwork.com)